Tests an early lipid-lowering care program after heart-related hospital stays
Tests an early cholesterol-lowering support program in adults with heart disease in Asia-Pacific.
Plain-language title generated from the registry record
Registry title: Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
Key facts
- Where
- Dalian, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who were admitted to hospital with a Type I heart attack (myocardial infarction). It tests a multi-part programme to lower cholesterol.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Admission to hospital for a Type I myocardial infarction (heart attack).
- Biomarker or test result
- LDL cholesterol must not be below 1.4mmol/L (54 mg/dL) at the start.
Main reasons for not taking part
- LDL below 1.4mmol/L (54 mg/dL) at baseline
- Cannot give contact details of their primary care doctor or general practitioner
- Cannot give written informed consent
- Unlikely to survive more than 12 months
Read by machine on 12 November 2026.
Where in China
- Affiliated Zhongshan Hospital of Dalian UniversityDalian, ChinaContact: Minglian GongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Stephen Nicholls
- Trial code
- NCT05325034
- Record updated
- 8 October 2026
- Original description
Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study.Read full original descriptionShow less
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific (GOAL-ASIA)
Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study.
Patients will be recruited during hospitalisation and be randomised to a multifaceted intervention to be delivered either 'early' (baseline) or 'late' (6 months), in a 1:1 fashion.
Inclusion: 18 years of age; Admission for Type I myocardial infarction.
Exclusion: LDL <1.4mmol/L at baseline; Unable to provide contact details of primary care physician/general practitioner; Unable to provide written informed consent; Unlikely to survive >12 months.